TITLE

Talecris Tries IPO Window Again: $850M

PUB. DATE
September 2009
SOURCE
Bioworld Week;9/21/2009, Vol. 17 Issue 38, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the plan of Talecris Biotherapeutics Holdings Corp. of Research Triangle Park to take the initial public offering (IPO) of Cumberland Pharmaceuticals Inc. in the U.S. It states that Talecris is trying to acquire the IPO of this blood products company for 850 million dollars. However, Cumberland is still facing some issues which credited from its previous IPO attempt.
ACCESSION #
44369828

 

Related Articles

  • Ironwood Spruces for IPO Bid; Joins Parade with $172M Filing. Boggs, Jennifer // BioWorld Today;11/24/2009, Vol. 20 Issue 227, p1 

    The article reports on an initial public offering (IPO) filed by biotechnology company Ironwood Pharmaceuticals Inc. Ironwood is planning to raise 172.5 million U.S. dollars in the IPO. Other U.S. biotechnology companies that undertook IPOs were Cumberland Pharmaceuticals Inc., which raised 85...

  • Plasma-Based Drug Firm Talecris Seeking $1B IPO.  // Bioworld Week;8/6/2007, Vol. 15 Issue 32, p2 

    The article reports that the Research Triangle Park, North Carolina-based biopharmaceutical company Talecris Biotherapeutics Holdings Corp. has filed for an initial public offering (IPO) to raise $1 billion. It states that Talecris plans to use the money to repay existing debt, cover unpaid...

  • Plasma-Based Drug Firm Talecris Seeking $1B IPO. Boggs, Jennifer // BioWorld Today;7/31/2007, Vol. 18 Issue 147, p1 

    The article reports that Research Triangle Park, North Carolina-based Talecris Biotherapeutics Holdings Corp. has filed for an initial public offering, with hopes of raising $1 billion. The firm is planning to use proceeds to repay existing debt and cover unpaid dividends. Information is...

  • Aldagen, not Talecris, will be IPO test case.  // Business North Carolina;Dec2009, Vol. 29 Issue 12, p28 

    The article compares the initial public offering (IPO) of Talecris Biotherapeutics Holdings Corp. and Aldagen Inc. in North Carolina. Talecris' IPO is considered the second-largest IPO in the U.S. in 2009. After more than two years that no Triangle region company had gone public, the truer IPO...

  • IPOs on Parade: Anthera Seeks $70M to Fund Cardio Studies.  // BioWorld Today;9/17/2009, Vol. 20 Issue 179, p3 

    The article focuses on the plan by Hayward, California-based Anthera Pharmaceuticals Inc. to launch an initial public offering (IPO) to raise 70 million dollars. The IPO is aimed at funding the company's cardiovascular disease program. The plan of the company came after Talecris Biotherapeutics...

  • Talecris IPO Trades Up on Debut; $950M Will Go to Debt, Investors. Morrison, Trista // BioWorld Today;10/2/2009, Vol. 20 Issue 190, p1 

    The article reports on the 950 million U.S. dollars raised by Talecris Biotherapeutics Holding Corp. in its initial public offering, making Talecris the second biggest company to test an IPO strategy. The company has generated a strong position in its plasma-derived products and projected that...

  • Financings Roundup.  // BioWorld Today;10/9/2009, Vol. 20 Issue 195, p7 

    The article reports on the closing of the initial public offering of Talecris Biotherapeutics Holdings Corp. on September 30, 2009. According to the company, the full overallotment option of 6 million shares has been exercised by the underwriters. The company sold a total of 56 million units at...

  • Talecris Tries IPO Window Again: Aiming for $850M to Pay Off Debt. Morrison, Trista // BioWorld Today;9/16/2009, Vol. 20 Issue 178, p1 

    The article reports on the initial public offering (IPO) of Talecris Biotherapeutics Holdings Corp., targeting $850 million in order to settle its debt to its investor, Cerberus Partners. Its debt runs to $1.1 billion as of June 30, 2009. It states that Talecris was censured for its unrealistic...

  • $3.4B Deal Moves Talecris into Grifols Plasma Fold. Moran, Nuala // BioWorld International;6/9/2010, Vol. 15 Issue 23, p1 

    The article reports on the merger between Talecris Biotherapeutics Holdings Corp. with Grifols. Eight months following Talecris' initial public offering (IPO), Grifols acquired Talecris for 3.4 billion U.S. dollars. The deal will be comprised of both cash and 85 million newly issued nonvoting...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics